Title of Invention	"A COMPOSITION USED IN TRANSDREMAL THERAPEUTIC SYSTEM IN PLASTER FORM FOR CONTROLLED RELEASE OF OESTRADIOL IN COMBINATION WITH NORETHISTERONE ACETATE"
Abstract	The present invention relates to a composition used in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients, said active ingredients being oestradiol and norethisterone acetate, and containing oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15 and an overall concentration of up to 25% by weight, which reservoir consists of one or more layers, is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino-containing polymer in a proportion from 0.05% to 30% by weight.

Title of Invention

"A COMPOSITION USED IN TRANSDREMAL THERAPEUTIC SYSTEM IN PLASTER FORM FOR CONTROLLED RELEASE OF OESTRADIOL IN COMBINATION WITH NORETHISTERONE ACETATE"

Abstract

The present invention relates to a composition used in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients, said active ingredients being oestradiol and norethisterone acetate, and containing oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15 and an overall concentration of up to 25% by weight, which reservoir consists of one or more layers, is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino-containing polymer in a proportion from 0.05% to 30% by weight.

Full Text	Transdermal therapeutic system comprising hormones and crystallization inhibitors The invention relates to a transdermal therapeutic system (TTS) for controlled release of oestradiol in combination with norethisterone acetate to the human skin. Oestradiol in combination with norethisterone acetate has a very low saturation solubility in the auxiliaries normally used to formulate transdermal therapeutic systems, such as polyacrylate adhesives, tackifiers, plasticizers and absorption improvers. As a result, the capacity to load a TTS with dissolved active ingredient is greatly limited, and/or, in the case of supersaturation, unwanted crystallization occurs during storage. Consequently, the proportion of dissolved active ingredients in the matrix is reduced, which has an adverse effect on their release. For combined preparations comprising oestradiol and norethisterone acetate, administration forms have been developed in which the active ingredients in a transdermal therapeutic system are contained in separate areas. However, manufacturing such TTSs is very expensive. Accommodating drying agents together with transdermal therapeutic systems in the primary packaging reduces the risk of recrystallization but is far from straightforward. DE-A 43 36 557 describes an active substance transdermal therapeutic system based on a pressure-sensitive adhesive which comprises rosin esters. It is prepared by kneading the components in the melt at temperatures between 100 and 140°C and then carrying out coating. Such high temperatures in the preparation of pharmaceutical forms carry with them the risk that degradation products may be formed in an unacceptably high amount. WO 95/30409 describes a topical polymer release system for the administration of certain active ingredients by means of a propellantless aerosol pump. The absence of adhesives is emphasized as an advantage. Additional components used include crystallization inhibitors/ stabilizers and/or penetration enhancers such as substituted cyclodextrins, Transcutol, urea and isoterpenes; the active substance combination of oestradiol and norethisterone acetate is not claimed. It is therefore an object of the invention to provide a stable, i.e. recrystallization-free, plaster comprising the active ingredients oestradiol and norethisterone acetate. It has surprisingly been found that in a transdermal therapeutic system having the features of the main claim this object is achieved by the use of an amino-containing polymer as crystallization inhibitor. Advantageous crystallization inhibitors used are polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, preferably in a molar ratio of 1:2:1, polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, poly amines and polyglucosamines. It has been found that the crystallization inhibitors are particularly suitable in a proportion of from 0.05 to 30% 'by weight. The formation of hydrogen bonds between the basic groups of the crystallization inhibitor and the mobile hydrogen atoms of the oestradiol molecule results in immobilization of oestradiol. Consequently, the concentration of freely mobile oestradiol in the matrix is reduced and crystallization prevented. The pressure-sensitive adhesive reservoir contains oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, preferably from 1:3 to 1:7, and in an overall concentration of up to 25% by weight. The reservoir may comprise a constituent from the group consisting of ageing inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizer being used in a concentration of from 0 to 5% by weight and the ageing inhibitor in a concentration of from 0.1 to 2% by weight. Suitable ageing inhibitors, plasticizers, antioxidants and absorption improvers are known to the person skilled in the art and are described, for example, in DE 37 43 949. In order to be able to apply the transdermal therapeutic system to the skin it is necessary for the system to have pressure-sensitive adhesive properties. In order to impart these properties to the transdermal therapeutic system of the invention use is made of polyacrylate pressure-sensitive adhesives in the form of solutions in organic solvents, known as solvent-based1 pressure-sensitive adhesives. It is also possible to use polyacrylate pressure-sensitive adhesives in the form of aqueous dispersions. Also suitable are hot-melt pressure-sensitive adhesives. These are free of solvent or dispersant and are applied from the melt. UV-crosslinkable aery late pressure-sensitive adhesives are also suitable. These are solvent-free and are applied using the conventional coating techniques. Subsequently, the polymer chains are cross linked by irradiation with UV light. This is necessary in order to give the pressure sensitive adhesive adequate cohesion. The reservoir of the transdermal therapeutic system may consist of a plurality of layers each with the same or different concentrations of active ingredient. The layer thickness of the reservoir is from 0.02 mm to 0.500 mm but preferably from 0.030 mm to 0.200 mm. The reservoir can be provided with an additional pressure sensitive adhesive layer and/or with a pressure-sensitive adhesive margin. This becomes necessary when the pressure-sensitive adhesive properties of the reservoir itself are inadequate. In accordance with the present invention it relates to a transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients, said active ingredients being oestradiol and norethisterone acetate, and containing oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15 and an overall concentration of up to 25% by weight, which reservoir consists of one or more layers, is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino containing polymer in a proportion from 0.05% to 30% by weight. The transdermal therapeutic system of the present invention is intended for therapeutic applications in human medicine. The invention is illustrated below on the basis of examples: Example 1 155. 08 g of Durotak 387-2287 (National Starch) (Polyacrylate pressure-sensitive adhesive (PSA) ) and 4.81 g of Eudragit E 100 (R O hm) (polyacrylate) are homogenized with stirring and, together with a suspension of 2.17 g of Eutanol G (Caesar and Loretz) (long-chain fatty alcohol) 0.30 g of aluminium acetylacetonate (Merck-Schuchardt), 1,29 g of Oestradiol hemihydrate and 8.33 g of norethisterone acetate, are dissolved in a solvent mixture comprising 27.98 g of ethyl acetate and 27.97 g of ethanol. The resultant adhesive solution is applied to a detachable protective layer of Hostaphan RN 100, siliconized on both sides, to give after drying an active substance matrix having a coated weight of 96.3 g/mJ. A backing layer impermeable to the active ingredients (0.015 mm thick polyester film) is laminated onto the resultant matrix. Subsequently, TTS patches measuring 40 cm2 are punched out. Examples 2-7 and comparison; Preparation takes place as described under Example 1 but with the starting materials and amounts specified in Table 1. Table 1: Composition [g] (Table Removed) The test for signs of recrystallization was conducted microscopically in transmitted light at 40 times magnification. The results are set out in Table 2. Table 2: Recrystallization (Table Removed) As evident from Table 2 the addition of crystallization inhibitors gives transdermal therapeutic systems which are free from crystallization, in contrast to the comparative example (without crystallization inhibitor) in "which there is considerable crystallization within a period of 3 months. WE CLAIM: 1. A composition used in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients, said active ingredients being oestradiol and norethisterone acetate, and containing oestradiol and nor ethisterone acetate in a weight ratio of from 1:2 to 1:15 and an overall concentration of up to 25% by weight, which reservoir consists of one or more layers, is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino-containing polymer in a proportion from 0.05% to 30% by weight. 2. A composition used in plaster form as claimed in claim 1 wherein the crystallization inhibitor is selected from polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl metharcylate, in particular in a molar ratio of 1:2:1, poly am inoam ides, polyaminoimidazolines, poly-etherurethaneamines, polyamines and polyglucosamines. 3. A composition used in plaster form as claimed in one or more of claims 1-2 wherein the reservoir comprises oestradiol and nor-ethisterone acetate in a weight ratio of from 1:3 to 1:7 4. A composition used in plaster form as claimed in one or more of claims 1-4 wherein the pressure-sensitive adhesive is a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive or a UV-crosslinkable adhesive. 5. A composition used in plaster form as claimed in one or more of claims 1-5 wherein the reservoir has a layer thickness of 0.02 mm-0.500 mm, preferably 0.030-0.200 mm. 6. A composition used in plaster form as claimed in one or more of claims 1-6 wherein the reservoir is provided with an additional pressure-sensitive adhesive layer and/or with a pressure-sensitive adhesive margin. 7. A composition used in plaster form substantially as herein described with reference to the foregoing description and the accompanying examples.

Full Text

Transdermal therapeutic system comprising hormones and crystallization inhibitors
The invention relates to a transdermal therapeutic system (TTS) for controlled release of oestradiol in combination with norethisterone acetate to the human skin.
Oestradiol in combination with norethisterone acetate has a very low saturation solubility in the auxiliaries normally used to formulate transdermal therapeutic systems, such as polyacrylate adhesives, tackifiers, plasticizers and absorption improvers. As a result, the capacity to load a TTS with dissolved active ingredient is greatly limited, and/or, in the case of supersaturation, unwanted crystallization occurs during storage. Consequently, the proportion of dissolved active ingredients in the matrix is reduced, which has an adverse effect on their release.
For combined preparations comprising oestradiol and norethisterone acetate, administration forms have been developed in which the active ingredients in a transdermal therapeutic system are contained in separate areas. However, manufacturing such TTSs is very expensive.
Accommodating drying agents together with transdermal therapeutic systems in the primary packaging reduces the risk of recrystallization but is far from straightforward.
DE-A 43 36 557 describes an active substance transdermal therapeutic system based on a pressure-sensitive adhesive which comprises rosin esters. It is prepared by kneading the components in the melt at temperatures between 100 and 140°C and then carrying out coating. Such high temperatures in the preparation of pharmaceutical forms carry with them the risk that degradation products may be formed in an unacceptably high amount.

WO 95/30409 describes a topical polymer release system for the administration of certain active ingredients by means of a propellantless aerosol pump. The absence of adhesives is emphasized as an advantage. Additional components used include crystallization inhibitors/ stabilizers and/or penetration enhancers such as substituted cyclodextrins, Transcutol, urea and isoterpenes; the active substance combination of oestradiol and norethisterone acetate is not claimed.
It is therefore an object of the invention to provide a stable, i.e. recrystallization-free, plaster comprising the active ingredients oestradiol and norethisterone acetate.
It has surprisingly been found that in a transdermal therapeutic system having the features of the main claim this object is achieved by the use of an amino-containing polymer as crystallization inhibitor. Advantageous crystallization inhibitors used are polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, preferably in a molar ratio of 1:2:1, polyaminoamides, polyaminoimidazolines,
polyetherurethaneamines, poly amines and polyglucosamines. It has been found that the crystallization inhibitors are particularly suitable in a proportion of from 0.05 to 30% 'by weight.
The formation of hydrogen bonds between the basic groups of the crystallization inhibitor and the mobile hydrogen atoms of the oestradiol molecule results in immobilization of oestradiol. Consequently, the concentration of freely mobile oestradiol in the matrix is reduced and crystallization prevented.

The pressure-sensitive adhesive reservoir contains oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, preferably from 1:3 to 1:7, and in an overall concentration of up to 25% by weight.
The reservoir may comprise a constituent from the group consisting of ageing inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizer being used in a concentration of from 0 to 5% by weight and the ageing inhibitor in a concentration of from 0.1 to 2% by weight.
Suitable ageing inhibitors, plasticizers, antioxidants and absorption improvers are known to the person skilled in the art and are described, for example, in DE 37 43 949.
In order to be able to apply the transdermal therapeutic system to the skin it is necessary for the system to have pressure-sensitive adhesive properties. In order to impart these properties to the transdermal therapeutic system of the invention use is made of polyacrylate pressure-sensitive adhesives in the form of solutions in organic solvents, known as solvent-based1 pressure-sensitive adhesives.
It is also possible to use polyacrylate pressure-sensitive adhesives in the form of aqueous dispersions.
Also suitable are hot-melt pressure-sensitive adhesives. These are free of solvent or dispersant and are applied from the melt.
UV-crosslinkable aery late pressure-sensitive adhesives are also suitable. These are solvent-free and are applied using the conventional coating techniques. Subsequently, the polymer chains are cross linked by irradiation with UV

light. This is necessary in order to give the pressure sensitive adhesive adequate cohesion.
The reservoir of the transdermal therapeutic system may consist of a plurality of layers each with the same or different concentrations of active ingredient.
The layer thickness of the reservoir is from 0.02 mm to 0.500 mm but preferably from 0.030 mm to 0.200 mm.
The reservoir can be provided with an additional pressure sensitive adhesive layer and/or with a pressure-sensitive adhesive margin. This becomes necessary when the pressure-sensitive adhesive properties of the reservoir itself are inadequate.
In accordance with the present invention it relates to a transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, a reservoir supersaturated with active ingredients, said active ingredients being oestradiol and norethisterone acetate, and containing oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15 and an overall concentration of up to 25% by weight, which reservoir consists of one or more layers, is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, and a detachable protective layer, characterized in that the crystallization inhibitor is an amino containing polymer in a proportion from 0.05% to 30% by weight.
The transdermal therapeutic system of the present invention is intended for therapeutic applications in human medicine.
The invention is illustrated below on the basis of examples: Example 1
155. 08 g of Durotak 387-2287 (National Starch) (Polyacrylate
pressure-sensitive adhesive (PSA) ) and
4.81 g of Eudragit E 100 (R O hm) (polyacrylate)
are homogenized with stirring and, together with a suspension of
2.17 g of Eutanol G (Caesar and Loretz) (long-chain fatty alcohol)
0.30 g of aluminium acetylacetonate (Merck-Schuchardt),
1,29 g of Oestradiol hemihydrate and
8.33 g of norethisterone acetate,

are dissolved in a solvent mixture comprising
27.98 g of ethyl acetate and 27.97 g of ethanol.
The resultant adhesive solution is applied to a detachable protective layer of Hostaphan RN 100, siliconized on both sides, to give after drying an active substance matrix having a coated weight of 96.3 g/mJ. A backing layer impermeable to the active ingredients (0.015 mm thick polyester film) is laminated onto the resultant matrix. Subsequently, TTS patches measuring 40 cm2 are punched out.
Examples 2-7 and comparison;
Preparation takes place as described under Example 1 but with the starting materials and amounts specified in Table 1.
Table 1: Composition [g]
(Table Removed)

The test for signs of recrystallization was conducted microscopically in transmitted light at 40 times magnification. The results are set out in Table 2.
Table 2: Recrystallization
(Table Removed)

As evident from Table 2 the addition of crystallization inhibitors gives transdermal therapeutic systems which are free from crystallization, in contrast to the comparative example (without crystallization inhibitor) in "which there is considerable crystallization within a period of 3 months.

WE CLAIM:
1. A composition used in plaster form for controlled release of
oestradiol in combination with norethisterone acetate,
comprising a backing layer, a reservoir supersaturated with
active ingredients, said active ingredients being oestradiol and
norethisterone acetate, and containing oestradiol and nor
ethisterone acetate in a weight ratio of from 1:2 to 1:15 and an
overall concentration of up to 25% by weight, which reservoir
consists of one or more layers, is attached to said backing
layer and is prepared using polyacrylate pressure-sensitive
adhesives and crystallization inhibitors, and a detachable
protective layer, characterized in that the crystallization
inhibitor is an amino-containing polymer in a proportion from
0.05% to 30% by weight.
2. A composition used in plaster form as claimed in claim 1
wherein the crystallization inhibitor is selected from polymers
based on butyl methacrylate, 2-dimethylaminoethyl
methacrylate and methyl metharcylate, in particular in a
molar ratio of 1:2:1, poly am inoam ides, polyaminoimidazolines,
poly-etherurethaneamines, polyamines and polyglucosamines.
3. A composition used in plaster form as claimed in one or more
of claims 1-2 wherein the reservoir comprises oestradiol and
nor-ethisterone acetate in a weight ratio of from 1:3 to 1:7
4. A composition used in plaster form as claimed in one or more
of claims 1-4 wherein the pressure-sensitive adhesive is a
solvent-based adhesive, a dispersion adhesive, a hot-melt
adhesive or a UV-crosslinkable adhesive.
5. A composition used in plaster form as claimed in one or more
of claims 1-5 wherein the reservoir has a layer thickness of
0.02 mm-0.500 mm, preferably 0.030-0.200 mm.
6. A composition used in plaster form as claimed in one or more
of claims 1-6 wherein the reservoir is provided with an
additional pressure-sensitive adhesive layer and/or with a
pressure-sensitive adhesive margin.

7. A composition used in plaster form substantially as herein described with reference to the foregoing description and the accompanying examples.

Documents:

in-pct-2000-00448-del-abstract.pdf

in-pct-2000-00448-del-assignment.pdf

in-pct-2000-00448-del-claims.pdf

in-pct-2000-00448-del-correspondence-others.pdf

in-pct-2000-00448-del-correspondence-po.pdf

in-pct-2000-00448-del-description (complete).pdf

in-pct-2000-00448-del-form-1.pdf

in-pct-2000-00448-del-form-13.pdf

in-pct-2000-00448-del-form-19.pdf

IN-PCT-2000-00448-DEL-Form-2.pdf

in-pct-2000-00448-del-form-3.pdf

in-pct-2000-00448-del-form-5.pdf

in-pct-2000-00448-del-gpa.pdf

in-pct-2000-00448-del-pct-210.pdf

in-pct-2000-00448-del-pct-304.pdf

in-pct-2000-00448-del-pct-306.pdf

in-pct-2000-00448-del-pct-331.pdf

in-pct-2000-00448-del-pct-409.pdf

in-pct-2000-00448-del-petition-137.pdf

in-pct-2000-00448-del-petition-others.pdf

« Previous Patent

Next Patent »

Patent Number

231819

Indian Patent Application Number

IN/PCT/2000/00448/DEL

PG Journal Number

13/2009

Publication Date

27-Mar-2009

Grant Date

09-Mar-2009

Date of Filing

21-Dec-2000

Name of Patentee

LTS LOHMANN THERAPIE-SYSTEM AG

Applicant Address

LOHMANNSTRASSE 2, D-56626 ANDERNACH, GERMANY.

Inventors:

#	Inventor's Name	Inventor's Address
1	KLEIN ROBERT, PETER	WICKINGERSTRASSE 3, D-56567 NEUWIED GERMANY.
2	MECONI, RAINHOLD	ALEMANNENSTRASSE 42, D-56567 NEUWIED GERMANY.
3	MULLER, WALTER	ENGERSERSTRASSE 56, D-56564 GERMANY.

PCT International Classification Number

A61K 9/00

PCT International Application Number

PCT/EP99/03922

PCT International Filing date

1999-06-08

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	198 28 273.7	1998-06-25	Germany